Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Clinical Proteomic Technologies for Cancer Initiative (CPTAC) Phase I
Not an EDRN Protocol

Clinical Proteomic Technologies for Cancer Initiative (CPTAC) Phase I

1002
Kinsinger, ChrisNational Cancer Institute

CPTAC Phase I 2006 - 2011, was developed to address the pre-analytical and analytical variability issues that are major barriers to the field of proteomics. These barriers were: (1) experimental design; (2) technological and technical aspects of protein identification; (3) variability related to biospecimens collection; (4) the processes of data acquisition, analysis, and reporting; (5) the lack of reproducible proteomic technologies; and (6) the lack of highly characterized and standardized reagents. See https://cptacdcc.georgetown.edu/cptac/study/list?scope=Phase+I for more information.

There are currently no biomarkers annotated for this protocol.


Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.

Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html